ECO ANIMAL HEALTH GROUP PLC

Director's Dealing • Aug 29, 2024

National Storage Mechanism | Additional information

RNS Number : 0512C

Eco Animal Health Group PLC

29 August 2024

29 August 2024

ECO Animal Health Group plc

("ECO" or the "Company")

Deferred Share Option Awards to Executive Directors

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that on 28 August 2024 nominal cost share options were granted under the Company's Deferred Bonus Plan ("DBS") over 143,452 ordinary shares in the Company (representing approximately 0.21 percent of the Company's issued share capital) to two Executive Directors listed below. These awards relate to the deferral of 33% of the annual bonus for Executive Directors earned in respect of the Company's financial year ended 31 March 2024.

Name	Position	Number of Deferred Share Options
David Hallas	Chief Executive Officer	82,437
Chris Wilks	Chief Financial Officer	61,015

As indicated in the Circular to shareholders dated 4 February 2021, the DBS has been established to allow the Remuneration Committee to require a significant part of the annual bonuses paid to Executive Directors to be deferred in exchange for an award of nominal cost options which vest after 3 years.

-Ends-

For further information please contact:

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)	020 8447 8899
Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher	020 7496 3000
Investec (Joint Broker) Gary Clarence Lydia Zychowska	020 7597 5970
Equity Development Hannah Crowe Matt Evans	020 7065 2692
ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson	020 3709 5700 ecoanimalhealth@consilium-comms.com

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

PDMR Notification - ECO DBS Deferred Share Option Awards

1.           

Details of the person discharging managerial responsibilities / person closely associated

a.            

Name

1.    David Hallas

2.    Chris Wilks

2.            

Reason for the notification

a.            

Position/status

1.    Chief Executive Officer

2.    Chief Financial Officer

b.            

Initial notification

/Amendment 

Initial notification

3.            

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.           

Name

Eco Animal Health Group Plc

b.           

LEI

2138009XN9DJ3YP70B55

4.            

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.            

Description of the

Financial instrument, type of instrument

Identification code

Options over ordinary shares of 5p each.

GB0032036807 

b.            

Nature of the transaction

Award of nominal cost share options under the Company's DBS.  

c.            

Price(s) and volume(s)

Numbers 1 and 2 in the left-hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above.

Price(s)	Volume(s)
1.    5p	82,437
2.    5p	61,015

d.            

Aggregated information

Aggregated volume

Price

n/a

e.            

Date of the transaction

28 August 2024

f.            

Place of the transaction

Outside a trading venue.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHPPMFTMTMTBJI